Sandra H. Thomas
YOU?
Author Swipe
View article: Yttrium-90 anti-CD25 BEAM conditioning for autologous hematopoietic cell transplantation in Peripheral T-cell lymphoma
Yttrium-90 anti-CD25 BEAM conditioning for autologous hematopoietic cell transplantation in Peripheral T-cell lymphoma Open
Peripheral T-cell lymphomas (PTCLs) have a poor prognosis with current treatments. High-dose chemotherapy followed by autologous hematopoietic cell transplant (AHCT) is used as a consolidation strategy after achieving clinical remission wi…
View article: Stimulation of Potent Humoral and Cellular Immunity via Synthetic Dual-Antigen MVA-Based COVID-19 Vaccine COH04S1 in Cancer Patients Post Hematopoietic Cell Transplantation and Cellular Therapy
Stimulation of Potent Humoral and Cellular Immunity via Synthetic Dual-Antigen MVA-Based COVID-19 Vaccine COH04S1 in Cancer Patients Post Hematopoietic Cell Transplantation and Cellular Therapy Open
Hematopoietic cell transplantation (HCT) and chimeric antigen receptor (CAR)-T cell patients are immunocompromised, remain at high risk following SARS-CoV-2 infection, and are less likely than immunocompetent individuals to respond to vacc…
View article: Data from The Cerebroventricular Environment Modifies CAR T Cells for Potent Activity against Both Central Nervous System and Systemic Lymphoma
Data from The Cerebroventricular Environment Modifies CAR T Cells for Potent Activity against Both Central Nervous System and Systemic Lymphoma Open
Lymphomas with central nervous system (CNS) involvement confer a worse prognosis than those without CNS involvement, and patients currently have limited treatment options. T cells genetically engineered with CD19-targeted chimeric antigen …
View article: Data from The Cerebroventricular Environment Modifies CAR T Cells for Potent Activity against Both Central Nervous System and Systemic Lymphoma
Data from The Cerebroventricular Environment Modifies CAR T Cells for Potent Activity against Both Central Nervous System and Systemic Lymphoma Open
Lymphomas with central nervous system (CNS) involvement confer a worse prognosis than those without CNS involvement, and patients currently have limited treatment options. T cells genetically engineered with CD19-targeted chimeric antigen …
View article: Supplementary Figures from The Cerebroventricular Environment Modifies CAR T Cells for Potent Activity against Both Central Nervous System and Systemic Lymphoma
Supplementary Figures from The Cerebroventricular Environment Modifies CAR T Cells for Potent Activity against Both Central Nervous System and Systemic Lymphoma Open
Supplementary Figures and Legends
View article: Supplementary Figures from The Cerebroventricular Environment Modifies CAR T Cells for Potent Activity against Both Central Nervous System and Systemic Lymphoma
Supplementary Figures from The Cerebroventricular Environment Modifies CAR T Cells for Potent Activity against Both Central Nervous System and Systemic Lymphoma Open
Supplementary Figures and Legends
View article: Supplemental Figure 3 from CD30 Downregulation, MMAE Resistance, and <i>MDR1</i> Upregulation Are All Associated with Resistance to Brentuximab Vedotin
Supplemental Figure 3 from CD30 Downregulation, MMAE Resistance, and <i>MDR1</i> Upregulation Are All Associated with Resistance to Brentuximab Vedotin Open
Supplemental Figure 3. Rhodamine Efflux Assay.
View article: Supplemental Figure 1 from CD30 Downregulation, MMAE Resistance, and <i>MDR1</i> Upregulation Are All Associated with Resistance to Brentuximab Vedotin
Supplemental Figure 1 from CD30 Downregulation, MMAE Resistance, and <i>MDR1</i> Upregulation Are All Associated with Resistance to Brentuximab Vedotin Open
Supplemental Figure 1. Karpas-R cultured in the absence of BV regains CD30-positivity.
View article: Data from CD30 Downregulation, MMAE Resistance, and <i>MDR1</i> Upregulation Are All Associated with Resistance to Brentuximab Vedotin
Data from CD30 Downregulation, MMAE Resistance, and <i>MDR1</i> Upregulation Are All Associated with Resistance to Brentuximab Vedotin Open
Brentuximab vedotin (BV) is an antibody–drug conjugate that specifically delivers the potent cytotoxic drug monomethyl auristatin E (MMAE) to CD30-positive cells. BV is FDA approved for treatment of relapsed/refractory Hodgkin lymphoma and…
View article: Supplemental Figure 2 from CD30 Downregulation, MMAE Resistance, and <i>MDR1</i> Upregulation Are All Associated with Resistance to Brentuximab Vedotin
Supplemental Figure 2 from CD30 Downregulation, MMAE Resistance, and <i>MDR1</i> Upregulation Are All Associated with Resistance to Brentuximab Vedotin Open
Supplemental Figure 2. Karpas-R cultured in the absence of BV have decreased IC50.
View article: Supplemental Figure 1 from CD30 Downregulation, MMAE Resistance, and <i>MDR1</i> Upregulation Are All Associated with Resistance to Brentuximab Vedotin
Supplemental Figure 1 from CD30 Downregulation, MMAE Resistance, and <i>MDR1</i> Upregulation Are All Associated with Resistance to Brentuximab Vedotin Open
Supplemental Figure 1. Karpas-R cultured in the absence of BV regains CD30-positivity.
View article: Supplemental Figure 3 from CD30 Downregulation, MMAE Resistance, and <i>MDR1</i> Upregulation Are All Associated with Resistance to Brentuximab Vedotin
Supplemental Figure 3 from CD30 Downregulation, MMAE Resistance, and <i>MDR1</i> Upregulation Are All Associated with Resistance to Brentuximab Vedotin Open
Supplemental Figure 3. Rhodamine Efflux Assay.
View article: Supplemental Figure 4 from CD30 Downregulation, MMAE Resistance, and <i>MDR1</i> Upregulation Are All Associated with Resistance to Brentuximab Vedotin
Supplemental Figure 4 from CD30 Downregulation, MMAE Resistance, and <i>MDR1</i> Upregulation Are All Associated with Resistance to Brentuximab Vedotin Open
Supplemental Figure 4. Immunohistochemistry for PgP on HL patient biopsy.
View article: Data from CD30 Downregulation, MMAE Resistance, and <i>MDR1</i> Upregulation Are All Associated with Resistance to Brentuximab Vedotin
Data from CD30 Downregulation, MMAE Resistance, and <i>MDR1</i> Upregulation Are All Associated with Resistance to Brentuximab Vedotin Open
Brentuximab vedotin (BV) is an antibody–drug conjugate that specifically delivers the potent cytotoxic drug monomethyl auristatin E (MMAE) to CD30-positive cells. BV is FDA approved for treatment of relapsed/refractory Hodgkin lymphoma and…
View article: Supplemental Figure 2 from CD30 Downregulation, MMAE Resistance, and <i>MDR1</i> Upregulation Are All Associated with Resistance to Brentuximab Vedotin
Supplemental Figure 2 from CD30 Downregulation, MMAE Resistance, and <i>MDR1</i> Upregulation Are All Associated with Resistance to Brentuximab Vedotin Open
Supplemental Figure 2. Karpas-R cultured in the absence of BV have decreased IC50.
View article: Supplemental Figure 4 from CD30 Downregulation, MMAE Resistance, and <i>MDR1</i> Upregulation Are All Associated with Resistance to Brentuximab Vedotin
Supplemental Figure 4 from CD30 Downregulation, MMAE Resistance, and <i>MDR1</i> Upregulation Are All Associated with Resistance to Brentuximab Vedotin Open
Supplemental Figure 4. Immunohistochemistry for PgP on HL patient biopsy.
View article: Supplemental Figure S3 from Favorable Activity and Safety Profile of Memory-Enriched CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in Adults with High-Risk Relapsed/Refractory ALL
Supplemental Figure S3 from Favorable Activity and Safety Profile of Memory-Enriched CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in Adults with High-Risk Relapsed/Refractory ALL Open
T cell subset analysis pre and post CAR T cell manufacturing
View article: Supplemental Figure S2 from Favorable Activity and Safety Profile of Memory-Enriched CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in Adults with High-Risk Relapsed/Refractory ALL
Supplemental Figure S2 from Favorable Activity and Safety Profile of Memory-Enriched CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in Adults with High-Risk Relapsed/Refractory ALL Open
Persistence of Tcm-derived CD19-CAR T cells
View article: Supplementary Table S2 from Favorable Activity and Safety Profile of Memory-Enriched CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in Adults with High-Risk Relapsed/Refractory ALL
Supplementary Table S2 from Favorable Activity and Safety Profile of Memory-Enriched CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in Adults with High-Risk Relapsed/Refractory ALL Open
Exploratory Analysis - Landmark at Day 28 Univariate Cox Proportional Hazards Models for Relapse-Free Survival
View article: Supplemental Figure S2 from Favorable Activity and Safety Profile of Memory-Enriched CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in Adults with High-Risk Relapsed/Refractory ALL
Supplemental Figure S2 from Favorable Activity and Safety Profile of Memory-Enriched CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in Adults with High-Risk Relapsed/Refractory ALL Open
Persistence of Tcm-derived CD19-CAR T cells
View article: Supplemental Figure S4 from Favorable Activity and Safety Profile of Memory-Enriched CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in Adults with High-Risk Relapsed/Refractory ALL
Supplemental Figure S4 from Favorable Activity and Safety Profile of Memory-Enriched CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in Adults with High-Risk Relapsed/Refractory ALL Open
Toxicity management algorithms
View article: Supplemental Figure S3 from Favorable Activity and Safety Profile of Memory-Enriched CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in Adults with High-Risk Relapsed/Refractory ALL
Supplemental Figure S3 from Favorable Activity and Safety Profile of Memory-Enriched CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in Adults with High-Risk Relapsed/Refractory ALL Open
T cell subset analysis pre and post CAR T cell manufacturing
View article: Data from Favorable Activity and Safety Profile of Memory-Enriched CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in Adults with High-Risk Relapsed/Refractory ALL
Data from Favorable Activity and Safety Profile of Memory-Enriched CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in Adults with High-Risk Relapsed/Refractory ALL Open
Purpose:A phase I/II study evaluating the safety and activity of memory-enriched CD19-directed chimeric antigen receptor (CD19-CAR) T cells in adults with relapsed/refractory B-cell acute lymphoblastic leukemia (ALL).Patients and Methods:I…
View article: Supplemental Figure S5 from Favorable Activity and Safety Profile of Memory-Enriched CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in Adults with High-Risk Relapsed/Refractory ALL
Supplemental Figure S5 from Favorable Activity and Safety Profile of Memory-Enriched CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in Adults with High-Risk Relapsed/Refractory ALL Open
CD19-CAR T cells in CSF
View article: Supplemental Figure S1 from Favorable Activity and Safety Profile of Memory-Enriched CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in Adults with High-Risk Relapsed/Refractory ALL
Supplemental Figure S1 from Favorable Activity and Safety Profile of Memory-Enriched CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in Adults with High-Risk Relapsed/Refractory ALL Open
Manufacturing schema for the clinical trial
View article: Supplemental Figure S4 from Favorable Activity and Safety Profile of Memory-Enriched CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in Adults with High-Risk Relapsed/Refractory ALL
Supplemental Figure S4 from Favorable Activity and Safety Profile of Memory-Enriched CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in Adults with High-Risk Relapsed/Refractory ALL Open
Toxicity management algorithms
View article: Supplemental Figure S1 from Favorable Activity and Safety Profile of Memory-Enriched CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in Adults with High-Risk Relapsed/Refractory ALL
Supplemental Figure S1 from Favorable Activity and Safety Profile of Memory-Enriched CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in Adults with High-Risk Relapsed/Refractory ALL Open
Manufacturing schema for the clinical trial
View article: Supplementary Table S1 from Favorable Activity and Safety Profile of Memory-Enriched CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in Adults with High-Risk Relapsed/Refractory ALL
Supplementary Table S1 from Favorable Activity and Safety Profile of Memory-Enriched CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in Adults with High-Risk Relapsed/Refractory ALL Open
Extramedullary disease at time of lymphodepletion